Madhan Selvaraj

Madhan Selvaraj, Ph.D., is a seasoned professional in the field of biomarker discovery and translational medicine, currently serving as Director of Biomarker Discovery & Qualification at Novo Nordisk since August 2017. Expertise includes driving translational medicine strategies, leading R&D teams to identify and qualify biomarkers, and developing frameworks to de-risk first-in-human trials. Prior roles at Novo Nordisk encompass Scientific Lead for early discovery, where Madhan chaired the Biology Innovation Group for Metabolism, and various positions in pharmacology and external innovation. Academic credentials include a Ph.D. in Metabolic Disease Biology from the Max Planck Society and a Master’s in Biotechnology from McGill University, supplemented by a Business Foundations Series certificate from The Wharton School. Previous research experience includes a postdoctoral fellow role at the Max Planck Society and contributions to vaccine efficacy at the National University of Singapore.